Related Experiment Videos

Cardiac dysfunction in cirrhosis - does adrenal function play a role? A hypothesis

Eleni Theocharidou1, Aleksander Krag, Flemming Bendtsen

  • 1The Royal Free Sheila Sherlock Liver Centre, Royal Free Hospital, Royal Free Hampstead NHS Trust and UCL, London, UK.

Liver International : Official Journal of the International Association for the Study of the Liver
|February 2, 2012
PubMed

Insights

Cirrhotic cardiomyopathy (CCM) involves heart dysfunction in advanced cirrhosis patients. Adrenal insufficiency (AI) may contribute to CCM, suggesting steroid therapy could be a potential treatment.

Area of Science:

  • Cardiology
  • Endocrinology
  • Hepatology

Background:

  • Cirrhotic cardiomyopathy (CCM) presents as impaired ventricular contractility and diastolic dysfunction in advanced cirrhosis patients.
  • CCM is clinically significant during physiological stress and may link to hepatorenal syndrome.
  • Adrenal insufficiency (AI) is found in ~10% of cirrhosis patients, featuring cardiac dysfunction and QT prolongation.

Purpose of the Study:

  • To explore the potential role of adrenal insufficiency (AI) in the pathogenesis of cirrhotic cardiomyopathy (CCM).
  • To investigate the shared pathophysiological mechanisms between CCM and AI-related cardiac dysfunction.
  • To consider the therapeutic implications of steroid replacement for CCM.

Main Methods:

  • Comparative analysis of cardiac dysfunction features in CCM and AI.
  • Examination of shared molecular pathways, including beta-adrenergic receptor regulation and catecholamine levels.
  • Review of existing literature on cardiac changes in AI and their reversal with steroid therapy.

Main Results:

  • Both CCM and AI exhibit impaired cardiac contractility, diastolic dysfunction, and QT interval prolongation.
  • Shared mechanisms include beta-adrenergic receptor down-regulation and elevated catecholamines.
  • Steroid replacement therapy is known to reverse cardiac dysfunction in AI.

Conclusions:

  • Adrenal insufficiency may be a contributing factor to cirrhotic cardiomyopathy.
  • The shared pathophysiology suggests AI could be a target for CCM treatment.
  • Formal evaluation of steroid replacement therapy for CCM is warranted due to potential therapeutic benefits.

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Adrenal Gland Disorders01:27

Adrenal Gland Disorders

Adrenal gland disorders manifest when the production of adrenal hormones deviates from the norm, resulting in either excessive or insufficient concentrations.
Adrenal insufficiency, characterized by insufficient cortisol and aldosterone production, leads to conditions like Addison's disease. This disorder, affecting the adrenal cortex, exhibits symptoms such as skin bronzing, dehydration, low blood pressure, fatigue, and weight loss. Congenital adrenal hyperplasia, a genetic ailment causing...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Imbalances in Cardiac Output01:26

Imbalances in Cardiac Output

The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to send blood...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...